Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.
OSTEOARTHRITIS
PRESENTED BY:
SAPEEDEH AFZAL
ROLL # 10
GROUP: A-1
ROAD MAP
• PROTECTIVE MECHANISM OF SYNOVIAL JOINTS
• WHAT IS OA
• EPIDEMIOLOGY
• DISTRIBUTION OF DISEASE.
• AETIOLOGY & RI...
PROTECTIVE MECHANISM OF
SYNOVIAL JOINTS
WHAT IS OSTEOARTHRITIS ???
Osteoarthritis is a
degenerative disease of
synovial joints
characterized by focal loss
of arti...
EPIDEMIOLOGY
• Weight bearing joints e.g. knee & hip joints.
• Age > 65 years.
– 80% have radiographic features.
– 25-30% ...
DISTRIBUTION OF DISEASE
ETIOLOGY
• PRIMARY / IDIOPATHIC:
When there is no obvious predisposing
factor. Common form of OA.
• SECONDARY:
When degene...
CAUSES OF SECONDARY OSTEOARTHRITIS
RISK FACTORS
AGEING
CONSTITUTIONAL
SUSCEPTIBILITY
MECHANICAL FACTORS
PATHOGENESIS
• Progressive destruction &
loss of articular cartilage
with an accompanying
peri-articular bone
response lea...
CLINICAL FEATURES
• Pain:
– Activity & weight-bearing
related, relieved by rest.
– Variable over time.
– Only one or few j...
CLINICAL FINDINGS IN NODAL
GENERALIZED OA
• Presentation typically in women. (40 & 50 years)
• Pain.
• Stiffness.
• Swelli...
CLINICAL FINDINGS IN KNEE OA
• Targets patello-femoral & medial tibio-femoral compartments of knee.
• Pain is localized to...
CLINICAL FINDINGS IN HIP OA
• Targets mostly superior aspect & less commonly medial aspect of joint.
• Pain is maximally d...
CLINICAL FINDINGS IN EARLY-
ONSET OA
• Before the age of 45 years.
• Single or multiple joint involvement.
• Typical signs...
CLINICAL FEATURES IN EROSIVE OA
• Preferentially targeting proximal IPJs.
• Common development of IPJ lateral instability....
DIFFERENTIAL DIAGNOSIS
FEATURES OSTEOARTHRITIS RHUEMATOID
ARTHRITIS
GOUT
PRESENCE OF SYMPTOMS
AFFECTING THE WHOLE
BODY:
Sy...
INVESTIGATIONS
• PLAIN X-RAY:
– JOINT SPACE
NARROWING
– SUBCHONDRAL
SCLEROSIS
MARGINAL OSTEOPHYTES
SUBCHONDRAL CYST
• BLOOD TEST:
– FBC NORMAL.
– ESR NORMAL.
– CRP NORMAL.
– RHEUMATOID FACTOR NEGATIVE.
• SYNOVIAL FLUID ANALYSIS:
– VISCOUS...
MANAGEMENT
NON-PHARMACOTHERAPY
– Full explanation of the condition via patient education:
• Properly position and support your neck a...
NON-PHARMACOTHERAPY
• Exercises:
• Aerobic conditioning.
• Muscle strengthening exercises.
• Reduction of adverse mechanic...
PHARMACOTHERAPY
PARACETAMOL
•Initial drug of choice
•Orally 1 gm 6-8 hourly
NSAIDs
•Indicated as needed.
•Oral e.g: ibupro...
SURGICAL TREATMENT
• Should be considered for those who do not give response to
pharmacotherapy.
– Osteotomy.
– Joint repl...
Osteoarthritis
Osteoarthritis
Osteoarthritis
Nächste SlideShare
Wird geladen in …5
×

Osteoarthritis

60.788 Aufrufe

Veröffentlicht am

osteoarthritis management

Veröffentlicht in: Bildung
  • Loggen Sie sich ein, um Kommentare anzuzeigen.

Osteoarthritis

  1. 1. OSTEOARTHRITIS PRESENTED BY: SAPEEDEH AFZAL ROLL # 10 GROUP: A-1
  2. 2. ROAD MAP • PROTECTIVE MECHANISM OF SYNOVIAL JOINTS • WHAT IS OA • EPIDEMIOLOGY • DISTRIBUTION OF DISEASE. • AETIOLOGY & RISK FACTORS • PATHOGENESIS • CLINICAL FEATURES • DIFFERENTIAL DIAGNOSIS • INVESTIGATIONS • MANAGEMENT
  3. 3. PROTECTIVE MECHANISM OF SYNOVIAL JOINTS
  4. 4. WHAT IS OSTEOARTHRITIS ??? Osteoarthritis is a degenerative disease of synovial joints characterized by focal loss of articular hyaline cartilage with proliferation of new bone & remodeling of joint contour.
  5. 5. EPIDEMIOLOGY • Weight bearing joints e.g. knee & hip joints. • Age > 65 years. – 80% have radiographic features. – 25-30% have symptoms. • More common in women. • Familial tendency.
  6. 6. DISTRIBUTION OF DISEASE
  7. 7. ETIOLOGY • PRIMARY / IDIOPATHIC: When there is no obvious predisposing factor. Common form of OA. • SECONDARY: When degenerative joint changes occur in response to a recognizable local or systemic factor.
  8. 8. CAUSES OF SECONDARY OSTEOARTHRITIS
  9. 9. RISK FACTORS AGEING CONSTITUTIONAL SUSCEPTIBILITY MECHANICAL FACTORS
  10. 10. PATHOGENESIS • Progressive destruction & loss of articular cartilage with an accompanying peri-articular bone response leads to exposure of sub-chondral bone which becomes sclerotic, with increased blood vascularity & cyst formation.
  11. 11. CLINICAL FEATURES • Pain: – Activity & weight-bearing related, relieved by rest. – Variable over time. – Only one or few joints involved. • Morning stiffness only brief <30 minutes. • Restricted functionality: – Capsular thickening. – Blocking by osteophytes.
  12. 12. CLINICAL FINDINGS IN NODAL GENERALIZED OA • Presentation typically in women. (40 & 50 years) • Pain. • Stiffness. • Swelling of one or few finger interphalangeal joints ( distal > proximal). • Heberden’s nodes (+/- Bouchard’s nodes). • Involvement of first carpometacarpal joint is common. • Predisposition to OA at other joints specially knees.
  13. 13. CLINICAL FINDINGS IN KNEE OA • Targets patello-femoral & medial tibio-femoral compartments of knee. • Pain is localized to anterior or medial aspect of knee & upper tibia. • Jerky gait. • Varus deformity. • Joint line &/or periarticular tenderness. • Weakness & wasting of quadriceps muscle. • Restricted extension & flexion. • Bony swelling around joint.
  14. 14. CLINICAL FINDINGS IN HIP OA • Targets mostly superior aspect & less commonly medial aspect of joint. • Pain is maximally deep in groin area. • Antalgic gait. • Weakness & wasting of muscles (quadriceps & gluteal). • Pain & restricted internal rotation with flexion.
  15. 15. CLINICAL FINDINGS IN EARLY- ONSET OA • Before the age of 45 years. • Single or multiple joint involvement. • Typical signs & symptoms of OA.
  16. 16. CLINICAL FEATURES IN EROSIVE OA • Preferentially targeting proximal IPJs. • Common development of IPJ lateral instability. • Sub-chondral erosions on x-rays. • Ankylosis of IPJs.
  17. 17. DIFFERENTIAL DIAGNOSIS FEATURES OSTEOARTHRITIS RHUEMATOID ARTHRITIS GOUT PRESENCE OF SYMPTOMS AFFECTING THE WHOLE BODY: Systemic symptoms are not present. Frequent fatigue and a general feeling of being ill are present Chills and a mild fever along with a general feeling of malaise may also accompany the severe pain and inflammation DURATION OF MORNING STIFFNESS: Morning stiffness lasts less than 30-60 mins; Morning stiffness lasts longer than 1 hour. Not seen NODULES: Heberden's & bouchard's nodes Heberden’s nodes are absent. PAIN WITH MOVEMENT: Movement increases pain Movement decreases pain AGE OF ONSET: Most commonly occurs in individuals over the age of 50. Usual age of onset is 20- 40 years. Usually over 35 yrs of age in men and after menopause in females LAB FINDINGS: Ra factor & anti-ccp antibody negative. Normal esr & c-reactive protein. Ra factor & anti-ccp antibody positive. Esr & c- reactive protein elevated. Joint fluid microscopy is diagnostic.
  18. 18. INVESTIGATIONS • PLAIN X-RAY: – JOINT SPACE NARROWING – SUBCHONDRAL SCLEROSIS
  19. 19. MARGINAL OSTEOPHYTES
  20. 20. SUBCHONDRAL CYST
  21. 21. • BLOOD TEST: – FBC NORMAL. – ESR NORMAL. – CRP NORMAL. – RHEUMATOID FACTOR NEGATIVE. • SYNOVIAL FLUID ANALYSIS: – VISCOUS WITH LOW TURBIDITY. – CPPD & CALCIUM PHOSPHATE. INVESTIGATIONS
  22. 22. MANAGEMENT
  23. 23. NON-PHARMACOTHERAPY – Full explanation of the condition via patient education: • Properly position and support your neck and back while sitting or sleeping. • Adjust furniture, such as raising a chair or toilet seat. • Avoid repeated motions of the joint, especially frequent bending. • Lose weight if you are overweight or obese, which can reduce pain and slow progression of OA. • Exercise each day. • Build confidence.
  24. 24. NON-PHARMACOTHERAPY • Exercises: • Aerobic conditioning. • Muscle strengthening exercises. • Reduction of adverse mechanical factors: • Weight loss. • Pacing of activities. • Appropriate footwear.
  25. 25. PHARMACOTHERAPY PARACETAMOL •Initial drug of choice •Orally 1 gm 6-8 hourly NSAIDs •Indicated as needed. •Oral e.g: ibuprofen & coxibs •Topically e.g: capsaicin 0.025% cream WEAK OPIOIDS •Occasionally required. •e.g: dihydrocodeine INTRA-ARTICULAR CORTICOSTEROIDS INJECTIONS •3-5 weekly. HYALURONIC INJECTIONSHYALURONIC INJECTIONS •Injections for 3-5 weeks.Injections for 3-5 weeks. •Pain relief for several months.
  26. 26. SURGICAL TREATMENT • Should be considered for those who do not give response to pharmacotherapy. – Osteotomy. – Joint replacement. – Total joint replacement.

×